Charles Rudin, MD @charlesrudin of Memorial Sloan Kettering Cancer Center @sloan_kettering discusses KEYNOTE-604: pembrolizumab versus placebo plus etoposide and platnium as a first-line therapy in SCLC.
Charles Rudin, MD on KEYNOTE-604: How Does This Compare to Other Trials? #ASCO2020 @charlesrudin #ASCO @sloan_kettering
